NCT00888563

Brief Summary

Background:

  • People with many different diseases have symptoms of fatigue, which is a general sense of tiredness; however, the causes are not fully understood. Fatigue symptoms may be related to a person s level of fitness, health, and blood chemistries.
  • Researchers are studying the potential role of plasma cytokines (signaling molecules) and hypothalamic-pituitary-adrenal (HPA) axis (part of the neuroendocrine system that controls stress) functioning in symptoms of fatigue. Objectives:
  • To characterize the symptoms of fatigue in healthy individuals.
  • To collect information on fatigue, pain, depression, stress, sleepiness, and quality of life from healthy adults of all ages.
  • To compare results obtained from people with various illnesses to better understand possible causes of fatigue that are associated with those diseases. Eligibility:
  • Physically and mentally healthy volunteers18 years of age or older who can speak and read the English language.
  • Exclusion criteria include individuals with a disease or condition causing significant fatigue (congestive heart failure, cancer, or sleep disorders), individuals taking medicines that cause fatigue (beta blockers, diuretics, or narcotics), and individuals who have a major psychiatric condition (major depression, anxiety disorder, or schizophrenia).
  • The following individuals may not participate: those who have two more alcoholic drinks per day, who use illicit drugs, or who drink more than 4 cups of coffee, 8 cups of soda or tea, or similar amounts of other caffeine-containing beverages a day, or eat more than 1 pound of chocolate per day; and individuals who worked evenings or night shifts in the past month.
  • Women who are pregnant or breastfeeding are not eligible. Design:
  • Participants must make two outpatient visits to the Clinical Center. Each visit will last 5 hours and participants must refrain from smoking and consuming alcohol and caffeine for at least 24 hours.
  • During the first study visit, researchers will conduct the following tests:
  • Psychiatric interview, medical history, pregnancy test, and drug test.
  • Urine test to measure the levels of stress hormones.
  • Questionnaires that measure fatigue, pain, depression, stress, daytime sleepiness, and activity.
  • Physical fitness test, including strength tests, walking tests, and physical activity monitoring.
  • Before the second study visit, patients must refrain from smoking and consuming caffeine and alcohol for at least 24 hours and have nothing, even water, by mouth after midnight. During the second study visit, the following tests will be conducted:
  • Stress hormone test (participant will receive a cortisol-releasing hormone).
  • Four intravenous blood draws to determine cytokine profiles, gene expression, and levels of stress hormones (immune and gentic analysis).
  • Participants will receive a small financial compensation for participation in the study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
114

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2009

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 23, 2009

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

April 24, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 27, 2009

Completed
8.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 16, 2017

Completed
Last Updated

December 9, 2019

Status Verified

November 16, 2017

First QC Date

April 24, 2009

Last Update Submit

December 6, 2019

Conditions

Keywords

FatigueDepressionHealthy VolunteerHV

Outcome Measures

Primary Outcomes (1)

  • fatigue score of healthy individuals using standardized questionnaires.

    study completed

Secondary Outcomes (1)

  • Physical activity, pain, depression, stress, and daytime sleepiness scores; the HPA axis function of healthy individuals; the proinflammatory cytokine profile and gene expression in response to stress.

    study completed

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • To be included, participants must meet the following:
  • Healthy, 18 years of age or older;
  • Speak and understand the English language.

You may not qualify if:

  • Participants with any one of the following will be excluded:
  • Inability to provide informed consent for the study;
  • Are unwilling or unable to cooperate with the study procedures or travel to NIH for the procedures;
  • Have a confirmed medical condition causing clinically significant fatigue symptom (e.g. congestive heart failure, cancer actively receiving therapy, sleep disorders);
  • Currently taking medications that cause fatigue (e.g. diuretics, beta blockers, narcotics);
  • Working late evening and night shifts within the past month;
  • Have severe psychiatric conditions (e.g. major depressive disorder, bipolar disorder, anxiety disorder, schizophrenia, drug and/or addiction abuse or dependence);
  • Report consuming more than 300mg of caffeine containing beverages (approximately 4 cups of coffee or 8 cups of soda or tea) or food (approximately 1 lb of chocolate) within 24 hours;
  • Reports consuming more than 2 servings of alcohol containing beverages every day and with detectable blood alcohol content (BAC) using breath analyzer (greater than 1 mg/dL of BAC);
  • Pregnant or lactating women.
  • Unable to refrain from smoking at least 4 hours prior to exercise testing sessions
  • Any medical condition that limits exercise performance (e.g. any condition with a ventilatory limitation during maximal exercise)
  • Any medical condition that affects participants safety with exercise (e.g.: severe heart disease, uncontrolled diabetes)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (5)

  • Levy M. Cancer fatigue: a review for psychiatrists. Gen Hosp Psychiatry. 2008 May-Jun;30(3):233-44. doi: 10.1016/j.genhosppsych.2008.01.004.

    PMID: 18433655BACKGROUND
  • Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol. 1996 Dec;9(6):456-60. doi: 10.1097/00019052-199612000-00011.

    PMID: 9007405BACKGROUND
  • Brola W, Ziomek M, Czernicki J. [Fatigue syndrome in chronic neurological disorders]. Neurol Neurochir Pol. 2007 Jul-Aug;41(4):340-9. Polish.

    PMID: 17874343BACKGROUND
  • Flynn S, Leete J, Shahim P, Pattinson C, Guedes VA, Lai C, Devoto C, Qu BX, Greer K, Moore B, van der Merwe A, Ekanayake V, Gill J, Chan L. Extracellular vesicle concentrations of glial fibrillary acidic protein and neurofilament light measured 1 year after traumatic brain injury. Sci Rep. 2021 Feb 16;11(1):3896. doi: 10.1038/s41598-021-82875-0.

  • Lukkahatai N, Walitt B, Espina A, Gelio A, Saligan LN. Understanding the Association of Fatigue With Other Symptoms of Fibromyalgia: Development of a Cluster Model. Arthritis Care Res (Hoboken). 2016 Jan;68(1):99-107. doi: 10.1002/acr.22626.

MeSH Terms

Conditions

FatigueDepression

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsBehavioral SymptomsBehavior

Study Officials

  • Leorey N Saligan, C.R.N.P.

    National Institute of Nursing Research (NINR)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 24, 2009

First Posted

April 27, 2009

Study Start

April 23, 2009

Study Completion

November 16, 2017

Last Updated

December 9, 2019

Record last verified: 2017-11-16

Locations